Ebola Virus‐Like Particle–Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge
Kelly L. Warfield(Tulane University), Sina Bavari(Epix Pharmaceuticals (United States)), Dana L. Swenson(United States Army Medical Research Institute of Infectious Diseases), M. Javad Aman(National Heart Lung and Blood Institute), Warren V. Kalina(Pfizer (United States)), Gene G. Olinger(Health Affairs)
Cited by 261
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937